555win cung cấp cho bạn một cách thuận tiện, an toàn và đáng tin cậy [kết quả xổ số 30 ngày miền bắc]
3 days ago · Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist.
3 days ago · Digital health company Noom has launched a compound pharmacy-made version of Novo Nordisk's obesity drug semaglutide to make the drug more accessible to consumers in the US.
2 days ago · Novo Nordisk has said it will offer diabetes therapy Ozempic at $499 per month for cash-paying customers in the US. Medical affairs is evolving.
2 days ago · Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making versions of one of its GLP-1 agonist drugs.
1 day ago · Novo Nordisk reined in its growth forecasts for the year in its second-quarter financial results update, blaming 'persistent use of compounded GLP-1s, slower-than-expected market expansion, and ...
2 days ago · Novo Nordisk has said it will offer diabetes therapy Ozempic at $499 per month for cash-paying customers in the US. Medical affairs is evolving.
2 days ago · Novo Nordisk has launched a direct-to-consumer (DTC) option for uninsured or under-insured people wanting to access its GLP-1 agonist weight-loss drug Wegovy, cutting the drug's price...
1 day ago · Shares in Novo Nordisk were trading down more than 20% today as it unexpectedly slashed its full-year sales guidance, citing a hit on demand for its GLP-1-based therapies for diabetes and...
2 days ago · Under pressure from rivals in the GLP-1 space, Novo Nordisk has been given a leg-up with a first-in-class approval for Wegovy in liver disease MASH
3 days ago · Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes.
Bài viết được đề xuất: